LONDON (Alliance News) - ValiRx PLC said Tuesday that it can begin the recruitment of patients in its phase I/II trial of developmental prostate cancer treatment VAL201, following the completion of all ethical opinions and the required regulatory permissions.
ValiRx has been working on preparing the trial following full approval from the UK's Medicine and Healthcare Products Regulatory Agency.
The life science company said the study will collect information to determine whether VAL201 is safe and well tolerated, and further analysis of the data will ascertain how it is processed by subjects and how it impacts their clinical condition.
Preliminary results from the first cohort are expected during the first quarter of 2015, ValiRx said.
The tolerability of the compound may also be assessed in patients with other advanced tumour types for which there is no standard effective therapy currently available.
"This is a key moment for any drug-discovery company and I and all at ValiRx look forward to collecting the human experimental data and updating shareholders on our results and on our continued further progress," said Chief Executive Satu Vainikka in a statement.
Shares in ValiRx are trading up 0.3% at 0.366 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)